Abstract
Introduction
The discovery of new cancer therapeutics has seen a significant shift towards
biologicals as an alternative to small molecule drugs. Targeted biologics
utilizing monoclonal antibody (mAb)-based technologies have rapidly developed
into one of the major market segments of the pharmaceutical industry. By
analyzing R&D pipelines and the platform technologies in use today, it is
possible to better predict where the market will be in the next decade and to
envisage which new innovative therapies will become market successes.
Research highlights
The second wave of therapeutic antibody technologies, encompassing optimized
full size, fully human antibodies as well as the bits and pieces of individual
antibody fragments and alternative binding domains/scaffolds is driving the
formation of innovative technology platforms. While biotechs have led the race
towards the discovery of novel technologies, big pharma has taken over the
reigns for the development of many of these future therapeutic drugs.
In this report, BioSeeker Group has surveyed and categorized the technology
platform status of over 100 companies and identified over 150 unique platforms
that are shaping the current and future pipeline of monoclonal antibody
therapeutics.
Scope of this report:
- A single source for market wide competing monoclonal antibody technologies
in oncology
- Thorough examination of the leading cancer therapeutic antibody
technologies
- The race towards the next generation of therapeutic antibodies
- Competing platforms for expression, delivery, and modification of
antibodies
This report will:
- improve your competitor analysis
- allow you to assess the strengths/weaknesses of competing technologies
- outline R&D alignments
- allow you to assess the direction of future technologies
Pages: 163
| 
View Cart
